Close Menu
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Okay, now exactly half of xAI’s founding team has left the company

February 11, 2026

Moderna says FDA refuses to review its application for flu vaccine

February 11, 2026

XAI Loses Another Cofounder, Jimmy Ba

February 11, 2026
Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
Facebook X (Twitter) Instagram
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
Home » DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump
Health

DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump

IQ TIMES MEDIABy IQ TIMES MEDIAJuly 1, 2007No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


Feb 2 (Reuters) – DaVita projected annual profit above estimates on Monday after reporting better-than-expected ​fourth-quarter results on steady demand for its ‌kidney dialysis services, sending its shares up 13% in after-hours ‌trading.

The company, which provides dialysis services at outpatient clinics and at home for patients with chronic kidney failure, signaled renewed momentum after dealing with ⁠rising patient care ‌and operating costs in recent quarters.

The Colorado-based company now expects its 2026 adjusted ‍profit per share to be between $13.60 and $15. Analysts were expecting it to be $12.65 per share, according to data ​compiled by LSEG.

Higher reimbursement rates and a ‌slight improvement in the mix and seasonal impact of flu vaccines helped lift fourth-quarter profit and revenue above expectations, the company said.

It had been dealing with the fallout from a ransomware attack ⁠in April that disrupted ​parts of its operations and ​exposed the personal data of 2.7 million people.

On an adjusted basis, it reported a ‍profit of $3.40 ⁠per share for the quarter ended December 31, above analysts’ estimates of $3.16 per share. The company ⁠reported quarterly revenue of $3.62 billion, compared to analysts’ estimates ‌of $3.50 billion.

(Reporting by Siddhi Mahatole in Bengaluru; ‌Editing by Vijay Kishore)



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
IQ TIMES MEDIA
  • Website

Related Posts

Moderna says FDA refuses to review its application for flu vaccine

February 11, 2026

Brain training game may help combat dementia for decades, study finds

February 10, 2026

New study examines possible risk factors linked to childhood food allergies

February 10, 2026
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Butler’s University’s new Deaf education curriculum draws concern

February 9, 2026

Student shot in Maryland high school and another student is in custody, police say

February 9, 2026

San Francisco teachers go on strike for first time in decades

February 9, 2026

Pentagon says it’s cutting ties with ‘woke’ Harvard

February 6, 2026
Education

Butler’s University’s new Deaf education curriculum draws concern

By IQ TIMES MEDIAFebruary 9, 20260

David Geeslin can still remember what it felt like to start learning American Sign Language…

Student shot in Maryland high school and another student is in custody, police say

February 9, 2026

San Francisco teachers go on strike for first time in decades

February 9, 2026

Pentagon says it’s cutting ties with ‘woke’ Harvard

February 6, 2026
IQ Times Media – Smart News for a Smarter You
Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2026 iqtimes. Designed by iqtimes.

Type above and press Enter to search. Press Esc to cancel.